Richard Gardner, DPM
Foot & Ankle Surgery · Henderson, NVNPI 1194068767
Payments from drug & device makers
What this record shows
33 manufacturers reported payments, led by Goode Surgical Inc at 53.0% of the total. Reporting peaked in 2022 at $2,203 and has fallen 91.3% since, to $192 in 2025.
Across 205 payments — averaging $44.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Goode Surgical Inc$5K
- Smith+Nephew$1K
- Treace Medical Concepts, Inc.$678
- Organogenesis Inc.$557
- Nevro Corp.$251
- Paratek Pharmaceuticals, Inc.$189
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,49449%
- Education$4,71251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Goode Surgical Inc | 22 | $4,876 |
| Smith+Nephew | 50 | $1,040 |
| Treace Medical Concepts, Inc. | 24 | $678 |
| Organogenesis Inc. | 13 | $557 |
| Nevro Corp. | 8 | $251 |
| Paratek Pharmaceuticals, Inc. | 17 | $189 |
| Alafair Biosciences, Inc. | 2 | $177 |
| Tactile Systems Technology Inc | 11 | $160 |
| Stryker | 10 | $160 |
| Bard Peripheral Vascular, Inc. | 2 | $155 |
| Amgen(2 entities) | 7 | $123 |
| Bioventus LLC | 4 | $100 |
| Rikco International, LLC | 2 | $85 |
| Abbott | 4 | $80 |
| Polynovo North America LLC | 2 | $78 |
| KCI USA, Inc. | 2 | $58 |
| Alfasigma USA, Inc. | 2 | $55 |
| Kerecis Limited | 1 | $45 |
| Misonix Inc | 2 | $39 |
| Pinnacle Transplant Technologies, LLC | 1 | $39 |
| GRT US Holding, Inc. | 6 | $37 |
| Osiris Therapeutics Inc. | 2 | $37 |
| Bsn Medical Inc | 1 | $29 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Solventum Corporation | 1 | $19 |
| Curonix LLC | 1 | $18 |
| Lifenet Health | 1 | $17 |
| Medela LLC | 1 | $17 |
| Sanara Medtech Inc. | 1 | $15 |
| Convatec Inc. | 1 | $15 |
| Orpyx Medical Technologies US Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Aroa Biosurgery Incorporated | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PuraPly$133
- Senza$132
- Rotarex$128
- Grafix PL PRIME$118
- VersaWrap$114
How this compares
$9,206 in reported general payments places this provider in the 75th percentile of 84 foot & ankle surgery providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 12 | $6,215 |
| Ketoconazole | 312 | $5,534 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 91 | $851 |
| Gentamicin Sulfate | 22 | $822 |
| Doxycycline Hyclate | 17 | $243 |
| Methylprednisolone | 42 | $231 |
| Mupirocin | 31 | $140 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $99 |
| Levofloxacin | 22 | $78 |
| Terbinafine Hcl | 12 | $77 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $56 |
| Meloxicam | 30 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,040 | $6,21512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 84 foot & ankle surgery providers in Nevada.
Other foot & ankle surgery in Henderson
- Roman SibelHenderson$309K
- Holman ChanHenderson$75K
- Jeremy TiltonHenderson$51K
- Gerald TorgesenHenderson$8K
- Troy McArthurHenderson$5K
- Philip LarsenHenderson$4K
- Roger ReedHenderson$3K
- Michael KooymanHenderson$2K
- Douglas StaceyHenderson$2K
- Joshua LisonbeeHenderson$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.